Biocon Biologics Ltd., a subsidiary of Biocon Ltd has announced that Abevmy 100 and 400 mg, a biosimilar of Bevacizumab co-developed with Viatris Inc. has received marketing authorization approval from the European Commission following the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
- Read more about Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/biocon-biologics-and-viatris-receive-european-commission-approval-for-biosimilar-bevacizumab
No comments:
Post a Comment